Omeros (NASDAQ:OMER - Get Free Report) updated its first quarter 2024 earnings guidance on Monday. The company provided EPS guidance of -0.630--0.580 for the period. The company issued revenue guidance of -.
Analyst Ratings Changes
Separately, StockNews.com cut shares of Omeros from a hold rating to a sell rating in a research note on Tuesday, March 26th.
Check Out Our Latest Stock Report on OMER
Omeros Trading Down 7.5 %
Shares of NASDAQ:OMER traded down $0.26 during trading on Monday, reaching $3.19. The company had a trading volume of 548,783 shares, compared to its average volume of 592,561. The company has a fifty day moving average of $3.88 and a two-hundred day moving average of $2.97. The stock has a market capitalization of $200.56 million, a P/E ratio of 9.97 and a beta of 1.34. Omeros has a 12 month low of $0.92 and a 12 month high of $7.80.
Hedge Funds Weigh In On Omeros
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in shares of Omeros by 258.0% in the 2nd quarter. BlackRock Inc. now owns 4,154,952 shares of the biopharmaceutical company's stock worth $22,603,000 after buying an additional 2,994,468 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Omeros by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 3,434,697 shares of the biopharmaceutical company's stock worth $20,642,000 after buying an additional 76,869 shares during the last quarter. Stifel Financial Corp increased its holdings in shares of Omeros by 4.7% in the 2nd quarter. Stifel Financial Corp now owns 2,056,835 shares of the biopharmaceutical company's stock worth $11,189,000 after buying an additional 93,215 shares during the last quarter. State Street Corp increased its holdings in shares of Omeros by 2.8% in the 1st quarter. State Street Corp now owns 1,412,609 shares of the biopharmaceutical company's stock worth $8,490,000 after buying an additional 38,498 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Omeros by 98.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,253,711 shares of the biopharmaceutical company's stock valued at $6,820,000 after purchasing an additional 621,819 shares during the last quarter. Institutional investors own 48.79% of the company's stock.
About Omeros
(
Get Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
